Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7660574 | 0.99 | TP53 (0.39) | TP53RXFP1POLBSMN1; SMN2MAPT | |
| SCHEMBL7663837 | 0.91 | TP53 (0.44) | TP53RXFP1POLBSMN1; SMN2MAPT | |
| SCHEMBL7663857 | 0.89 | RXFP1 (0.40) | TP53RXFP1POLBSMN1; SMN2MAPT | |
| SCHEMBL7660922 | 0.88 | PDE4A (0.37) | POLB | |
| SCHEMBL7652540 | 0.87 | PDE4A (0.37) | TP53POLBMAPT | |
| SCHEMBL8516330 | 0.86 | TP53 (0.42) | TP53RXFP1POLBMAPT | |
| SCHEMBL7654113 | 0.85 | KDM4E (0.33) | KDM4EALDH1A1HPGD | |
| SCHEMBL7853098 | 0.84 | KDM4E (0.33) | TP53SMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL7664799 | 0.83 | PDE4A (0.37) | TP53POLBMAPT | |
| SCHEMBL8516409 | 0.83 | TP53 (0.43) | TP53RXFP1POLBSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6458792-B1 | MEDICAMENT FOR THE TREATMENT OF INFLAMMATORY, IMMUNOLOGICAL, BRONCHOPULMONARY, CARDIOVASCULAR, ONCOLOGICAL OR CNS-DEGENERATIVE DISORDERS. | ASTRAZENECA AB (SE) | 2002-10-01 | — | — | US | disclosed |
| EP-1071683-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2001-01-31 | — | — | EP | disclosed |
| WO-1999046264-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 1999-09-16 | — | — | WO | disclosed |